Details


Species	Human
Species subgroup
Subgroup type
Sequence Name	IGHV1-2*i01
IUIS Name	IGHV1-2*06
Alternative names	IGHV1-2p06, IGHV1-206
Affirmation Level	1
Full Sequence
Coding Sequence
Functionality	F
Inference Type	Rearranged Only
Alternative names	IGHV1-2p06, IGHV1-206
Paralogs

Evidence

The table below lists the submissions, and the inferences within them, on which this published sequence is based. The list may be short when the sequence is first published, containing, for example, reference to just a single submission, but is expected to grow over time as additional inferences are submitted.

'Sequence Match' indicates whether the inference exactly matches the sequence, and clicking on the tick or cross will provide an alignment. Mismatches may be caused, for example, by the inclusion of leader sequences, or nucleotides in the inference which do not in IARC's opinion have sufficient evidence for inclusion in the sequence.

Submission ID	Accession No	Subject ID	Genotype Name	Sequence Name	Sequence Match
S00004	MH779621	B12	B12	IGHV1-2*02_S4497

Supporting Observations

Sequences in other published genotypes which have been identified by IARC and support the inference:

No Items

Observations in VDJbase

Inferred sequences in VDJbase that match this sequence:

No Items

Un-rearranged Observations

Un-rearranged sequence observations that support this sequence:

No Items

Additional Information


Sequence ID	A00003
Curator address	Dept. of Immunotechnology, Lund University, Lund, Sweden
Version	3
Release Date	2019-04-12
Release Notes	A trailing “.” in the sequence indicates IARC’s opinion that the sequence is likely to contain additional 3’ nucleotides for which there is insufficient evidence to make an affirmation.
Locus	IGH
Sequence Type	V
Gene Subgroup	1
Gene Designation	2
Allele Designation	i01

Acknowledgements

Individuals acknowledged as contributing to this sequence:

No Items

Notes

Notes are added by IARC reviewers.


Originally approved by IARC on March 9, 2018. “The sequence was inferred by Martin Corcoran using IgDiscover, and by Duncan Ralph using both Partis and TIgGER. The number of unique CDR3 used by sequences with exact matches to the inferred germline allele represents 1.9% [NOTE: 1.77% using the herein used approach to define number of exact matches] of all unique CDR3 associated to exact IGHV matches in the genotype,according to IgDiscover. There were at least 739 unique rearrangements, utilizing 19 D genes and 7 J genes, and hundreds of exact matches. The allele was the more frequently utilized allele, with an expression ratio of 70:30 with the 01 allele. The inference was supported by haplotype analysis using IGHJ602/03. The sequence is present in the IgPdb as IGHV1-2p06. The full length sequence was first reported to IgPdb in 2015 by Scheepers and colleagues (see J Immunol 194:4371-8) from genomic sequencing, and it was separately reported to IgPdb in 2016 by Kirik and colleagues (see Mol Immunol 87:12-22), as an inference from VDJ rearrangements.” In line with IARC policy, the submitted sequence was recognized up to and including nucleotide 319. (April 12, 2019) A trailing “.” in the sequence indicates IARC’s opinion that the sequence is likely to contain additional 3’ nucleotides for which there is insufficient evidence to make an affirmation. The allele was incorporated into IMGT on July 24, 2018 as IGHV1-2*06.

Originally approved by IARC on March 9, 2018.

“The sequence was inferred by Martin Corcoran using IgDiscover, and by Duncan Ralph using both Partis and TIgGER. The number of unique CDR3 used by sequences with exact matches to the inferred germline allele represents 1.9% [NOTE: 1.77% using the herein used approach to define number of exact matches] of all unique CDR3 associated to exact IGHV matches in the genotype,according to IgDiscover. There were at least 739 unique rearrangements, utilizing 19 D genes and 7 J genes, and hundreds of exact matches. The allele was the more frequently utilized allele, with an expression ratio of 70:30 with the *01 allele. The inference was supported by haplotype analysis using IGHJ6*02/*03. The sequence is present in the IgPdb as IGHV1-2*p06. The full length sequence was first reported to IgPdb in 2015 by Scheepers and colleagues (see J Immunol 194:4371-8) from genomic sequencing, and it was separately reported to IgPdb in 2016 by Kirik and colleagues (see Mol Immunol 87:12-22), as an inference from VDJ rearrangements.”

In line with IARC policy, the submitted sequence was recognized up to and including nucleotide 319.

(April 12, 2019) A trailing “.” in the sequence indicates IARC’s opinion that the sequence is likely to contain additional 3’ nucleotides for which there is insufficient evidence to make an affirmation.

The allele was incorporated into IMGT on July 24, 2018 as IGHV1-2*06.

Attachments

No Items

History

History logs the times and reasons for the publication of each version of this sequence.


Mats Ohlin 2018-12-21 11:57:50	Version 1 published Submission published by IARC on Dec 21, 2018.


Andrew Collins 2019-04-03 04:11:05	Version 2 published This version was created to include details highlighting the fact that the published sequence was affirmed up to and including nucleotide 319, but the submitted sequence was one nucleotide longer.


Mats Ohlin 2019-04-12 14:53:18	Version 3 published A trailing “.” in the sequence indicates IARC’s opinion that the sequence is likely to contain additional 3’ nucleotides for which there is insufficient evidence to make an affirmation.

Changes from previous version

	v2	v3
Notes		changed

Versions

All published versions of this sequence.

Sequence Name	IMGT Name	Alternative names	Inference Type	Affirmation Level	Version	Date
IGHV1-2*i01	IGHV1-2*06	IGHV1-2p06, IGHV1-206	Rearranged Only	1	1	2018-12-21
IGHV1-2*i01	IGHV1-2*06	IGHV1-2p06, IGHV1-206	Rearranged Only	1	2	2019-04-03
IGHV1-2*i01	IGHV1-2*06	IGHV1-2p06, IGHV1-206	Rearranged Only	1	3	2019-04-12